The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment

Triple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new...

Full description

Bibliographic Details
Main Authors: Yi-Zhi Zhu, Di Xu, Zhen Liu, Tian Tian, Fei Deng, Wen-Juan Tang, Yang Wu, Wei Zhang, Jin-Hai Tang
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Journal of Nanomaterials
Online Access:http://dx.doi.org/10.1155/2020/4943270
id doaj-aa6e9e21e3b0489486242bf3bfa4ff98
record_format Article
spelling doaj-aa6e9e21e3b0489486242bf3bfa4ff982020-11-25T03:27:49ZengHindawi LimitedJournal of Nanomaterials1687-41101687-41292020-01-01202010.1155/2020/49432704943270The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer TreatmentYi-Zhi Zhu0Di Xu1Zhen Liu2Tian Tian3Fei Deng4Wen-Juan Tang5Yang Wu6Wei Zhang7Jin-Hai Tang8Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaSchool of Clinical Medicine, Xuzhou Medical University, Xuzhou 221004, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaTriple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new target treatment strategies for TNBC are of urgent need. It was speculated that glutamine could be a potential target because it is in high demand by TNBC. In this study, we found that the transporter for glutamine, ASCT2 (solute carrier family 1 member 5 (SLC1A5)), is highly expressed in TNBC by analysis of data from The Cancer Genome Atlas (TCGA) and experiments in vitro. Based on this, glutamine was grafted onto a polymeric drug carrier in order to develop a tumor-targeting drug delivery system for treatment of TNBC. Firstly, pH-responsive glutamine-PEG5000-b-PAE10000 (Gln-PEG-b-PAE) copolymers were synthesized using Fmoc-PEG5000-b-PAE10000 (Fmoc-PEG-b-PAE) copolymers. Then, Gln-PEG-b-PAE@DOX micelles were prepared by loading DOX to Gln-PEG-b-PAE copolymer using a solvent casting technology. In vitro, Gln-PEG-b-PAE@DOX micelles exhibited pH-dependent micellization-decellularization behavior; namely, they can rapidly release DOX in acidic environment of pH 6.0 but release very slowly in physiological condition. Moreover, glutamine competition experiment showed that Gln-PEG-b-PAE@DOX micelles had the ability to target MDA-MB-231 cells. Compared to free DOX, Gln-PEG-b-PAE@DOX micelles had significantly greater cytotoxic effect and antiproliferative activity against MDA-MB-231 cells. In vivo, compared to free DOX and mPEG-b-PAE@DOX micelles, Gln-PEG-b-PAE@DOX micelles significantly inhibited tumor growth in tumor-bearing mice. Therefore, Gln-PEG-b-PAE@DOX micelles, as a tumor-targeting drug delivery system, may provide a new method for the treatment of TNBC.http://dx.doi.org/10.1155/2020/4943270
collection DOAJ
language English
format Article
sources DOAJ
author Yi-Zhi Zhu
Di Xu
Zhen Liu
Tian Tian
Fei Deng
Wen-Juan Tang
Yang Wu
Wei Zhang
Jin-Hai Tang
spellingShingle Yi-Zhi Zhu
Di Xu
Zhen Liu
Tian Tian
Fei Deng
Wen-Juan Tang
Yang Wu
Wei Zhang
Jin-Hai Tang
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
Journal of Nanomaterials
author_facet Yi-Zhi Zhu
Di Xu
Zhen Liu
Tian Tian
Fei Deng
Wen-Juan Tang
Yang Wu
Wei Zhang
Jin-Hai Tang
author_sort Yi-Zhi Zhu
title The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
title_short The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
title_full The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
title_fullStr The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
title_full_unstemmed The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
title_sort synthesis of glutamine-functionalized block polymer and its application in triple-negative breast cancer treatment
publisher Hindawi Limited
series Journal of Nanomaterials
issn 1687-4110
1687-4129
publishDate 2020-01-01
description Triple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new target treatment strategies for TNBC are of urgent need. It was speculated that glutamine could be a potential target because it is in high demand by TNBC. In this study, we found that the transporter for glutamine, ASCT2 (solute carrier family 1 member 5 (SLC1A5)), is highly expressed in TNBC by analysis of data from The Cancer Genome Atlas (TCGA) and experiments in vitro. Based on this, glutamine was grafted onto a polymeric drug carrier in order to develop a tumor-targeting drug delivery system for treatment of TNBC. Firstly, pH-responsive glutamine-PEG5000-b-PAE10000 (Gln-PEG-b-PAE) copolymers were synthesized using Fmoc-PEG5000-b-PAE10000 (Fmoc-PEG-b-PAE) copolymers. Then, Gln-PEG-b-PAE@DOX micelles were prepared by loading DOX to Gln-PEG-b-PAE copolymer using a solvent casting technology. In vitro, Gln-PEG-b-PAE@DOX micelles exhibited pH-dependent micellization-decellularization behavior; namely, they can rapidly release DOX in acidic environment of pH 6.0 but release very slowly in physiological condition. Moreover, glutamine competition experiment showed that Gln-PEG-b-PAE@DOX micelles had the ability to target MDA-MB-231 cells. Compared to free DOX, Gln-PEG-b-PAE@DOX micelles had significantly greater cytotoxic effect and antiproliferative activity against MDA-MB-231 cells. In vivo, compared to free DOX and mPEG-b-PAE@DOX micelles, Gln-PEG-b-PAE@DOX micelles significantly inhibited tumor growth in tumor-bearing mice. Therefore, Gln-PEG-b-PAE@DOX micelles, as a tumor-targeting drug delivery system, may provide a new method for the treatment of TNBC.
url http://dx.doi.org/10.1155/2020/4943270
work_keys_str_mv AT yizhizhu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT dixu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT zhenliu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT tiantian thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT feideng thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT wenjuantang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT yangwu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT weizhang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT jinhaitang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT yizhizhu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT dixu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT zhenliu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT tiantian synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT feideng synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT wenjuantang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT yangwu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT weizhang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
AT jinhaitang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment
_version_ 1715208118414082048